The Schall Law Firm is investigating Qiagen N.V. for potential securities law violations after the company gave conflicting guidance on its QuantiFERON product's growth. In February 2026, Qiagen forecasted 6-7% growth for QuantiFERON, but by April, the CFO revised this, projecting sales to remain flat through 2026 and only normalize growth in 2027. This discrepancy has prompted a shareholder fraud investigation, and affected investors are encouraged to contact the law firm for potential legal action. The case highlights risks of misleading corporate forecasts impacting investor decisions.
Australian brand STYLD. has partnered with Mattel to release a limited-edition Barbie-themed Christmas collection featuring summer-inspired, reusable entertaining items in Candy Cane Pink and Peppermint Green. The collection includes insulated carafe...
Kirby McInerney LLP is investigating Fervo Energy for potential securities law violations following the company's Q2 2026 earnings report and a critical research report. Fervo's shares fell sharply after it disclosed possible transmission issues at i...
Airbnb reports a surge in fall travel, with 60% of Americans planning weekend getaways, especially families with infants. Gen Z is driving a trend called lore-tripping, seeking unique local stories, while sports fans engage in groundhopping to iconic...
Ethena (ENA) price fell 15.76% to $0.201476 on October 13, 2026, driven by net inflows of 1.45 million tokens to centralized exchanges, signaling strong selling pressure. On-chain data reveals that 79.4% of reported trading volume is wash trading, in...
A $300,000 investment in the iShares iBoxx $ High Yield Corporate Bond ETF (HYG) generated $18,255 in taxable interest income over 12 months, but the total return was only $5,550 due to a share price decline. Investors pay ordinary income tax on the ...
